Who are FOY-305's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, Pradaxa, Pradaxa (Dabigatran etexilate), Dabigatran etexilate (Pradaxa), prasugrel/bivalirudin, r-Hirudin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/foy-305.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FOY-305 — Competitive Intelligence Brief

FOY-305 (FOY-305) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct thrombin inhibitor. Area: Cardiovascular.

phase 3 Direct thrombin inhibitor Factor IIa (Thrombin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

FOY-305 (FOY-305) — Ono Pharmaceutical Co. Ltd. FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FOY-305 TARGET	FOY-305	Ono Pharmaceutical Co. Ltd	phase 3	Direct thrombin inhibitor	Factor IIa (Thrombin)
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Pradaxa	dabigatran-etexilate	Boehringer Ingelheim	marketed	Direct thrombin inhibitor	Thrombin (serine protease)	2010-01-01
Pradaxa (Dabigatran etexilate)	Pradaxa (Dabigatran etexilate)	Bayer	marketed	Direct thrombin inhibitor (anticoagulant)	Thrombin (Factor IIa)
Dabigatran etexilate (Pradaxa)	Dabigatran etexilate (Pradaxa)	Bayer	marketed	Direct thrombin inhibitor (DTI)	Thrombin (Factor IIa)
prasugrel/bivalirudin	prasugrel/bivalirudin	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Antiplatelet agent + Direct thrombin inhibitor combination	P2Y12 receptor (prasugrel); Thrombin (bivalirudin)
r-Hirudin	r-Hirudin	MinaPharm Pharmaceuticals	marketed	Direct thrombin inhibitor	Thrombin (Factor IIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-08-31 — Pradaxa · 7866474 · US
2028-03-02 — Pradaxa · 7866474*PED · US
2031-01-20 — Pradaxa · 9034822 · US
2031-07-20 — Pradaxa · 9034822*PED · US

Sponsor landscape (Direct thrombin inhibitor class)

Bayer · 2 drugs in this class
Boehringer Ingelheim · 1 drug in this class
MinaPharm Pharmaceuticals · 1 drug in this class
Ono Pharmaceutical Co. Ltd · 1 drug in this class
The Medicines Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOY-305 — Competitive Intelligence Brief. https://druglandscape.com/ci/foy-305. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab